PubRank

Immunogenicity and Safety Trial of the HIV-1 Tat Vaccine (ISS T-002)

Clinical Trial ID NCT00751595

PubWeight™ 9.10‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00751595

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 2005 1.23
2 Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One 2010 1.13
3 Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS 2006 1.12
4 SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J Med Primatol 2000 0.99
5 Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine 2009 0.97
6 Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J Infect Dis 2003 0.95
7 The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. AIDS 2008 0.95
8 The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine 2009 0.95
9 Challenges in HIV Vaccine Research for Treatment and Prevention. Front Immunol 2014 0.93
10 The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology 2014 0.92
11 HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies. PLoS One 2012 0.91
12 HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology 2015 0.89
13 Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev Recent Clin Trials 2009 0.87
14 HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. Retrovirology 2016 0.76
15 Perspectives for immunotherapy: which applications might achieve an HIV functional cure? Oncotarget 2016 0.75
Next 100